Alnylam Pharmaceuticals
ALNY
NASDAQ
IPO2004
about ALNY
Alnylam Pharmaceuticals is a biopharmaceutical company focused on developing innovative treatments using RNA interference (RNAi) technology to target and silence specific genes, aiming to address a wide range of diseases by reducing the production of harmful proteins in the body.
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $353.66 | $356.84 | $350.47 | $46.9B | 353.81K |
| eps |
price to earnings |
price to sales |
operating margin |
profit margin |
yield |
| +$1.91 | 17545.00 | 38.59 | 29.46% | 20.10% | 0% |